Pyrazole-based cathepsin S inhibitors with improved cellular potency
摘要:
High potency pyrazole-based noncovalent inhibitors of human cathepsin S (CatS) were developed by modification of the benzo-fused 5-membered ring heterocycles found in earlier series of Cats inhibitors. Although substitutions on this heterocyclic framework had a moderate impact on enzymatic potency, dramatic effects on cellular activity were observed. Optimization afforded indole- and benzothiophene-derived analogues that were high affinity Cats inhibitors (IC50 = 20-40 nM) with good cellular potency (IC50 = 30-340 nM). (c) 2007 Elsevier Ltd. All rights reserved.
Method for treating allergies using substituted pyrazoles
申请人:Butler R. Christopher
公开号:US20050101587A9
公开(公告)日:2005-05-12
A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.
使用取代吡唑烷治疗过敏症状的方法,包括特应性过敏症状。
Substituted pyrazoles
申请人:Butler R. Christopher
公开号:US20050245576A1
公开(公告)日:2005-11-03
Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.
Substituted pyrazoles and methods of treatment with substituted pyrazoles
申请人:Butler R. Christopher
公开号:US20070117785A1
公开(公告)日:2007-05-24
Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases or allergic conditions, including atopic allergic conditions, mediated by cathepsin S are described.
Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors
作者:Darin J. Gustin、Clark A. Sehon、Jianmei Wei、Hui Cai、Steven P. Meduna、Haripada Khatuya、Siquan Sun、Yin Gu、Wen Jiang、Robin L. Thurmond、Lars Karlsson、James P. Edwards
DOI:10.1016/j.bmcl.2005.01.045
日期:2005.3
A novel series of competitive, reversible cathepsin S (Cats) inhibitors was discovered and optimized. The 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety was found to be an effective replacement for the 4-arylpiperazin-1-yl group found in our earlier series of Cats inhibitors. This replacement imparted improved PK properties as well as decreased off-target activity. Optimization of the ketobenzimidazole moiety led to the discovery of the lead compound JNJ 10329670, which represents a novel class of selective, noncovalent, reversible, and orally bioavailable inhibitors of cathepsin S. (c) 2005 Elsevier Ltd. All rights reserved.
A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES